Ikena Oncology, Inc. (IKNA)
|Net Income (ttm)||-44.26M|
|Trading Day||April 9|
|Day's Range||15.75 - 19.02|
|52-Week Range||15.75 - 37.61|
Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purch...
BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and s...
BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer...
Ikena Oncology, a phase 1 oncology biotech developing small molecule inhibitor therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Ikena Oncology, Inc. has filed to go public with an IPO on the NASDAQ.
Ikena Oncology is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned an... [Read more...]
|IPO Date |
Mar 26, 2021
Mark Manfredi, Ph.D.
|Stock Exchange |
|Ticker Symbol |
In 2020, Ikena Oncology's revenue was $9.19 million, a decrease of -33.15% compared to the previous year's $13.75 million. Losses were -$44.26 million, 163.2% more than in 2019.